VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
Becton, Dickinson and Company vs Eli Lilly and Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Becton, Dickinson and Company
BDX · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Becton, Dickinson and Company's moat claims, evidence, and risks.
View BDX analysisEli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.
View LLY analysisComparison highlights
- Moat score: both at 66 / 100.
- Segment focus: Becton, Dickinson and Company has 5 segments (29.5% in Medical Essentials); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Strong.
- Moat breadth: Becton, Dickinson and Company has 7 moat types across 3 domains; Eli Lilly and Company has 5 across 2.
Primary market context
Becton, Dickinson and Company
Medical Essentials
Single-use medical consumables and specimen collection systems
Global
Healthcare providers and clinical labs
Manufacturer
29.5%
Eli Lilly and Company
Cardiometabolic Health
Branded cardiometabolic pharmaceuticals (type 2 diabetes, obesity, and related metabolic/cardiovascular conditions; especially incretin therapies)
Global
Patients via prescribers; payers/PBMs; wholesaler & pharmacy channels
Drug developer, manufacturer, and marketer
65.5%
Side-by-side metrics
Moat coverage
Shared moat types
Becton, Dickinson and Company strengths
Eli Lilly and Company strengths
Segment mix
Becton, Dickinson and Company segments
Full profile >Medical Essentials
Competitive
Connected Care
Oligopoly
BioPharma Systems
Oligopoly
Interventional
Competitive
Life Sciences
Oligopoly
Eli Lilly and Company segments
Full profile >Cardiometabolic Health
Oligopoly
Oncology
Competitive
Immunology
Competitive
Neuroscience
Competitive
Other
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.